Skip to main content
Top
Published in: European Journal of Nuclear Medicine and Molecular Imaging 2/2018

Open Access 01-02-2018 | Original Article

68Ga-PSMA-11 PET/CT in primary staging of prostate carcinoma: preliminary results on differences between black and white South-Africans

Authors: Mike Sathekge, Thabo Lengana, Alex Maes, Mariza Vorster, JanRijn Zeevaart, Ismaheel Lawal, Thomas Ebenhan, Christophe Van de Wiele

Published in: European Journal of Nuclear Medicine and Molecular Imaging | Issue 2/2018

Login to get access

Abstract

Purpose

The incidence of prostate cancer is 60% higher and the mortality rate is two- to three-times greater in black versus white men. We report on differences in 68Ga-PSMA-11 PET/CT imaging findings in 77 black South-African (BSAs) and 18 white South-African (WSAs) treatment-naïve primary prostate carcinoma (PPC) patients.

Methods

68Ga-PSMA-11 PET/CT imaging findings were compared to histological, biochemical and morphological imaging data. Patients were grouped into three Gleason grade groups (GG), GG 1 (scores 3 + 3 and 3 + 4), GG2 (scores 4 + 3 and 4 + 4) and GG3 (scores 9 and 10), and the PSA difference among the groups was determined. Inter-racial difference in SUVmax of the primary tumor as well as its correlation with serum PSA were also determined.

Results

Ninety-three out of 95 PPC where readily identified on 68Ga-PSMA-11 PET/CT imaging. Median PPC SUVmax and serum PSA values proved significantly higher (p = 0.033 and p = 0.003) in GG3 patients (median 16.4 and 180 ng/ml) when compared to GG1 patients (median 9.6 and 25.1 ng/ml) or GG2 patients (median 8.8 and 46.2 ng/ml). SUVmax significantly correlated with serum PSA-values (r = 0.377 (p = 0.0001)). Age, frequency of lymph node involvement and distant metastases, and GGs (p ≥ 0.153) were similar in BSAs and WSAs, both median serum PSA-values as well as SUVmax values proved significantly higher in BSAs when compared to WSAs, respectively, 81.6 ng/ml versus 14.5 ng/ml (p = 0.0001) and 11.9 versus 4.38 (p = 0.004). Moreover, Gleason-score normalized median SUVmax values proved 2.5 times higher in BSAs when compared to WSAs (p = 0.005).

Conclusion

SUVmax values proved significantly related to GG and to be significantly higher in BSAs when compared to WSAs. Also, SUVmax significantly correlated with serum PSA values, which was significantly higher in BSAs when compared with WSAs.
Literature
1.
2.
go back to reference Evans S, Metcalfe C, Ibrahim F, Persad R, Ben-Shlomo Y. Investigating black-white differences in prostate cancer prognosis: a systematic review and meta-analysis. Int J Cancer. 2008;123(2):430–5.CrossRefPubMed Evans S, Metcalfe C, Ibrahim F, Persad R, Ben-Shlomo Y. Investigating black-white differences in prostate cancer prognosis: a systematic review and meta-analysis. Int J Cancer. 2008;123(2):430–5.CrossRefPubMed
3.
go back to reference Powell I. The precise role of ethnicity and family history on aggressive prostate cancer: a review analysis. Arch Esp Urol. 2011;64(8):711–9.PubMedPubMedCentral Powell I. The precise role of ethnicity and family history on aggressive prostate cancer: a review analysis. Arch Esp Urol. 2011;64(8):711–9.PubMedPubMedCentral
4.
go back to reference Mahal B, Aizer A, Ziehr D, Hyatt AS, Lago-Hernandez C, Choueiri TK, et al. Racial disparities in prostate cancer-specific mortality in men with low-risk prostate cancer. Clin Genitourin Cancer. 2014;12(4):189–95.CrossRef Mahal B, Aizer A, Ziehr D, Hyatt AS, Lago-Hernandez C, Choueiri TK, et al. Racial disparities in prostate cancer-specific mortality in men with low-risk prostate cancer. Clin Genitourin Cancer. 2014;12(4):189–95.CrossRef
6.
go back to reference Afshar-Oromieh A, Malcher A, Eder M, Eisenhut M, Linhart HG, Hadaschik BA, et al. PET imaging with a [68Ga]gallium-labelled PSAM ligand for the diagnosis of prostate cancer: biodsitribution in humans and first evaluation of tumour lesions. Eur J Nucl Med Mol Imaging. 2013;40(3):486–95.CrossRefPubMed Afshar-Oromieh A, Malcher A, Eder M, Eisenhut M, Linhart HG, Hadaschik BA, et al. PET imaging with a [68Ga]gallium-labelled PSAM ligand for the diagnosis of prostate cancer: biodsitribution in humans and first evaluation of tumour lesions. Eur J Nucl Med Mol Imaging. 2013;40(3):486–95.CrossRefPubMed
7.
go back to reference Afshar-Oromieh A, Zechmann CM, Malcher A, Eder M, Eisenhut M, Linhart HG, et al. Comparison of PET imaging with a (68)Ga-labelled PSMA ligand and (18)F-choline-based PET/CT for the diagnosis of recurrent prostate cancer. Eur J Nucl Med Mol Imaging. 2014;41(1):11–20.CrossRefPubMed Afshar-Oromieh A, Zechmann CM, Malcher A, Eder M, Eisenhut M, Linhart HG, et al. Comparison of PET imaging with a (68)Ga-labelled PSMA ligand and (18)F-choline-based PET/CT for the diagnosis of recurrent prostate cancer. Eur J Nucl Med Mol Imaging. 2014;41(1):11–20.CrossRefPubMed
8.
go back to reference Afshar-Oromieh A, Avtzi E, Giesel FL, Holland-Letz T, Linhart HG, Eder M, et al. The diagnostic value of PET/CT imaging with the (68)Ga-labelled PSMA ligand HBED-CC in the diagnosis of recurrent prostate cancer. Eur J Nucl Med Mol Imaging. 2015;42(2):197–209.CrossRefPubMed Afshar-Oromieh A, Avtzi E, Giesel FL, Holland-Letz T, Linhart HG, Eder M, et al. The diagnostic value of PET/CT imaging with the (68)Ga-labelled PSMA ligand HBED-CC in the diagnosis of recurrent prostate cancer. Eur J Nucl Med Mol Imaging. 2015;42(2):197–209.CrossRefPubMed
9.
go back to reference Eiber M, Maurer T, Souvatzoglou M, Beer AJ, Ruffani A, Haller B, et al. Evaluation of hybrid 68Ga-PSMA ligand PET/CT in 248 patients with biochemical recurrence after radical prostatectomy. J Nucl Med. 2015;56(5):668–74.CrossRefPubMed Eiber M, Maurer T, Souvatzoglou M, Beer AJ, Ruffani A, Haller B, et al. Evaluation of hybrid 68Ga-PSMA ligand PET/CT in 248 patients with biochemical recurrence after radical prostatectomy. J Nucl Med. 2015;56(5):668–74.CrossRefPubMed
10.
go back to reference Afshar-Oromieh A, Holland-Letz T, Giesel FL, Kratochwil C, Mier W, Haufe S, et al. Diagnostic performance of 68Ga-PSMA-II (HBED-CC) PET/CT in patients with recurrent prostate cancer: evaluation in 1007 patients. Eur J Nucl Med Mol Imaging. 2017;44(8):1258–68.CrossRefPubMedPubMedCentral Afshar-Oromieh A, Holland-Letz T, Giesel FL, Kratochwil C, Mier W, Haufe S, et al. Diagnostic performance of 68Ga-PSMA-II (HBED-CC) PET/CT in patients with recurrent prostate cancer: evaluation in 1007 patients. Eur J Nucl Med Mol Imaging. 2017;44(8):1258–68.CrossRefPubMedPubMedCentral
11.
go back to reference Eder M, Schäfer M, Bauder-Wüst U, Hull WE, Wangler C, Mier W, et al. 68Ga-complex lipophilicity and the targeting property of a urea-based PSMA inhibitor for PET imaging. Bio Conjug Chem. 2012;23(4):688–97. Eder M, Schäfer M, Bauder-Wüst U, Hull WE, Wangler C, Mier W, et al. 68Ga-complex lipophilicity and the targeting property of a urea-based PSMA inhibitor for PET imaging. Bio Conjug Chem. 2012;23(4):688–97.
12.
go back to reference Zechmann CM, Afshar-Oromieh A, Armor T, Stubbs JB, Mier W, Hadaschik B, et al. Radiation dosimetry and first therapy results with a (124)I/(131)I-labeled small molecule (MIP-1095) targeting PSMA for prostate cancer therapy. Eur J Nucl Med Mol Imaging. 2014;41(7):1280–92.CrossRefPubMedPubMedCentral Zechmann CM, Afshar-Oromieh A, Armor T, Stubbs JB, Mier W, Hadaschik B, et al. Radiation dosimetry and first therapy results with a (124)I/(131)I-labeled small molecule (MIP-1095) targeting PSMA for prostate cancer therapy. Eur J Nucl Med Mol Imaging. 2014;41(7):1280–92.CrossRefPubMedPubMedCentral
13.
go back to reference Ebenhan T, Vorster M, Marjanovic-Painter B, Wagener J, Suthiram J, Modiselle M, et al. Development of a single vial kit solution for radiolabeling of 68Ga-DKFZ-PSMA-11 and its performance in prostate cancer patients. Molecules. 2015;20(8):14860–78.CrossRefPubMed Ebenhan T, Vorster M, Marjanovic-Painter B, Wagener J, Suthiram J, Modiselle M, et al. Development of a single vial kit solution for radiolabeling of 68Ga-DKFZ-PSMA-11 and its performance in prostate cancer patients. Molecules. 2015;20(8):14860–78.CrossRefPubMed
14.
go back to reference Maurer T, Gschwend JE, Rauscher I, Souvatzoglou M, Haller B, Weirich G, et al. Diagnostic efficacy of (68)Gallium-PSMA positron emission tomography compared to conventional imaging for lymph node staging of 130 consecutive patients with intermediate to high risk prostate cancer. J Urol. 2016;195(5):1436–43.CrossRefPubMed Maurer T, Gschwend JE, Rauscher I, Souvatzoglou M, Haller B, Weirich G, et al. Diagnostic efficacy of (68)Gallium-PSMA positron emission tomography compared to conventional imaging for lymph node staging of 130 consecutive patients with intermediate to high risk prostate cancer. J Urol. 2016;195(5):1436–43.CrossRefPubMed
15.
go back to reference Budäus L, Leyh-Bannurah S, Salomon G, Michl U, Heinzer H, Huland H, et al. Initial experience of (68)Ga-PSMA PET/CT imaging in high-risk prostate cancer patients prior to radical prostatectomy. Eur Urol. 2016;69(3):393–6.CrossRefPubMed Budäus L, Leyh-Bannurah S, Salomon G, Michl U, Heinzer H, Huland H, et al. Initial experience of (68)Ga-PSMA PET/CT imaging in high-risk prostate cancer patients prior to radical prostatectomy. Eur Urol. 2016;69(3):393–6.CrossRefPubMed
16.
go back to reference Uprimny C, Kroiss A, Decristoforo C, Fritz J, von Guggenberg E, Kendler D, et al. 68Ga-PSMA-11 PET/CT in primary staging of prostate cancer: PSA and Gleason score predict the intensity of tracer accumulation in the primary tumour. Eur J Nucl Med Mol Imaging. 2017;44(6):941–9.CrossRefPubMed Uprimny C, Kroiss A, Decristoforo C, Fritz J, von Guggenberg E, Kendler D, et al. 68Ga-PSMA-11 PET/CT in primary staging of prostate cancer: PSA and Gleason score predict the intensity of tracer accumulation in the primary tumour. Eur J Nucl Med Mol Imaging. 2017;44(6):941–9.CrossRefPubMed
17.
go back to reference Rajasekaran A, Anilkumar G, Christiansen J. Is prostate specific membrane antigen a multifunctional protein? Am J Physiol Cell Physiol. 2005;288(5):C975–81.CrossRefPubMed Rajasekaran A, Anilkumar G, Christiansen J. Is prostate specific membrane antigen a multifunctional protein? Am J Physiol Cell Physiol. 2005;288(5):C975–81.CrossRefPubMed
18.
go back to reference Heston W. Characterization and glutamyl preferring carboxypeptidase function of prostate specific membrane antigen: a novel folate hydrolase. Urology. 1997;49(3A Suppl):104–12.CrossRefPubMed Heston W. Characterization and glutamyl preferring carboxypeptidase function of prostate specific membrane antigen: a novel folate hydrolase. Urology. 1997;49(3A Suppl):104–12.CrossRefPubMed
19.
go back to reference Yao V, Parwani A, Maier C, Heston W, Bacich D. Moderate expression of prostate-specific membrane antigen, a tissue differentiation antigen and folate hydrolase, facilitates prostate carcinogenesis. Cancer Res. 2008;68(21):9070–7.CrossRefPubMedPubMedCentral Yao V, Parwani A, Maier C, Heston W, Bacich D. Moderate expression of prostate-specific membrane antigen, a tissue differentiation antigen and folate hydrolase, facilitates prostate carcinogenesis. Cancer Res. 2008;68(21):9070–7.CrossRefPubMedPubMedCentral
20.
go back to reference Yao V, Berkman C, Choi J, O'Keefe DS, Bacich DJ, et al. Expression of prostate-specific membrane antigen (PSMA), increases cell folate uptake and proliferation and suggests a novel role for PSMA in the uptake of the non-polyglutamated folate, folic acid. Prostate. 2010;70(3):305–16.PubMed Yao V, Berkman C, Choi J, O'Keefe DS, Bacich DJ, et al. Expression of prostate-specific membrane antigen (PSMA), increases cell folate uptake and proliferation and suggests a novel role for PSMA in the uptake of the non-polyglutamated folate, folic acid. Prostate. 2010;70(3):305–16.PubMed
21.
go back to reference Koochekpour S, Majumdar S, Azabdaftari G, Attwood K, Scioneaux R, Subramani D, et al. Serum glutamate levels correlate with Gleason score and glutamate blockade decreases proliferation, migration and invasion and induces apoptosis in prostate cancer cells. Clin Cancer Res. 2012;18(21):5888–901.CrossRefPubMedPubMedCentral Koochekpour S, Majumdar S, Azabdaftari G, Attwood K, Scioneaux R, Subramani D, et al. Serum glutamate levels correlate with Gleason score and glutamate blockade decreases proliferation, migration and invasion and induces apoptosis in prostate cancer cells. Clin Cancer Res. 2012;18(21):5888–901.CrossRefPubMedPubMedCentral
22.
go back to reference Lapidus R, Tiffany C, Isaacs J, Slusher BS. Prostate-specific membrane antigen (PSMA) enzyme activity is elevated in prostate cancer cells. Prostate. 2000;45(4):350–4.CrossRefPubMed Lapidus R, Tiffany C, Isaacs J, Slusher BS. Prostate-specific membrane antigen (PSMA) enzyme activity is elevated in prostate cancer cells. Prostate. 2000;45(4):350–4.CrossRefPubMed
23.
go back to reference Conway R, Petrovic N, Li Z, Heston W, Wu D, Shapiro L. Prostate-specific membrane antigen regulates angiogenesis by modulating integrin signal transduction. Mol Cell Biol. 2006;26(14):5310–24.CrossRefPubMedPubMedCentral Conway R, Petrovic N, Li Z, Heston W, Wu D, Shapiro L. Prostate-specific membrane antigen regulates angiogenesis by modulating integrin signal transduction. Mol Cell Biol. 2006;26(14):5310–24.CrossRefPubMedPubMedCentral
24.
go back to reference Rajasekaran S, Christiansen J, Schmid I, Oshima E, Ryazantsev S, Sakamoto K, et al. Prostate-specific membrane antigen associates with anaphase-promoting complex and induces chromosomal instability. Mol Cancer Ther. 2008;7(7):2142–51.CrossRefPubMedPubMedCentral Rajasekaran S, Christiansen J, Schmid I, Oshima E, Ryazantsev S, Sakamoto K, et al. Prostate-specific membrane antigen associates with anaphase-promoting complex and induces chromosomal instability. Mol Cancer Ther. 2008;7(7):2142–51.CrossRefPubMedPubMedCentral
25.
go back to reference Tsui P, Rubenstein M, Guinan P. Correlation between PSMA and VEGF expression as markers for LNCaP tumor angiogenesis. J Biomed Biotechnol. 2005;2005(3):287–90.CrossRefPubMedPubMedCentral Tsui P, Rubenstein M, Guinan P. Correlation between PSMA and VEGF expression as markers for LNCaP tumor angiogenesis. J Biomed Biotechnol. 2005;2005(3):287–90.CrossRefPubMedPubMedCentral
26.
go back to reference Perico M, Grasso S, Brunelli M, Martignoni G, Munari E, Moiso E, et al. Prostate-specific membrane antigen (PSMA) assembles a macromolecular complex regulating growth and survival of prostate cancer cells “in vitro” and correlating with progression “in vivo”. Oncotarget 2016; 7(45): 74189-74202. Perico M, Grasso S, Brunelli M, Martignoni G, Munari E, Moiso E, et al. Prostate-specific membrane antigen (PSMA) assembles a macromolecular complex regulating growth and survival of prostate cancer cells “in vitro” and correlating with progression “in vivo”. Oncotarget 2016; 7(45): 74189-74202.
27.
go back to reference Shuch B, Mikhail M, Satagopan J, Lee P, Yee H, Chang C, et al. Racial disparity of epidermal growth factor receptor expression in prostate cancer. J Clin Oncol. 2004;22(23):4725–9.CrossRefPubMed Shuch B, Mikhail M, Satagopan J, Lee P, Yee H, Chang C, et al. Racial disparity of epidermal growth factor receptor expression in prostate cancer. J Clin Oncol. 2004;22(23):4725–9.CrossRefPubMed
28.
go back to reference Sachpekidis C, Kopka K, Eder M, Hadaschik BA, Freitag MT, Pan L, et al. 68Ga-PSMA-11 Dynamic PET/CT Imaging in Primary Prostate Cancer. Clin Nucl Med. 2016;41(11):e473–9.CrossRefPubMed Sachpekidis C, Kopka K, Eder M, Hadaschik BA, Freitag MT, Pan L, et al. 68Ga-PSMA-11 Dynamic PET/CT Imaging in Primary Prostate Cancer. Clin Nucl Med. 2016;41(11):e473–9.CrossRefPubMed
29.
go back to reference Kabalin J, McNeal J, Johnstone I, Stamey T. Serum prostate-specific antigen and the biologic progression of prostate cancer. Urology. 1995;46(1):65–70.CrossRefPubMed Kabalin J, McNeal J, Johnstone I, Stamey T. Serum prostate-specific antigen and the biologic progression of prostate cancer. Urology. 1995;46(1):65–70.CrossRefPubMed
30.
go back to reference Pierozazio P, Desai M, McCann T, Benson M, McKierann J. The relationship between preoperative prostate-specific antigen and biopsy Gleason sum in men undergoing radical retropubic prostatectomy: a novel assessment of traditional predictors of outcome. BJU Int. 2009;103(1):38–42.CrossRef Pierozazio P, Desai M, McCann T, Benson M, McKierann J. The relationship between preoperative prostate-specific antigen and biopsy Gleason sum in men undergoing radical retropubic prostatectomy: a novel assessment of traditional predictors of outcome. BJU Int. 2009;103(1):38–42.CrossRef
31.
go back to reference Koochekpour S, Buckles E, Shourideh M, Hu S, Chandra D, Zabaleta J, et al. Androgen receptor mutations and polymorphisms in African American prostate cancer. Int J Biol Sci. 2014;5(6):643–51.CrossRef Koochekpour S, Buckles E, Shourideh M, Hu S, Chandra D, Zabaleta J, et al. Androgen receptor mutations and polymorphisms in African American prostate cancer. Int J Biol Sci. 2014;5(6):643–51.CrossRef
32.
go back to reference Mavropoulos J, Partin A, Amling C, Terris MK, Kane CJ, Aronson WJ, et al. Do racial differences in prostate size explain higher serum PSA concentrations among black men? Urology. 2007;69(6):1138–42.CrossRefPubMedPubMedCentral Mavropoulos J, Partin A, Amling C, Terris MK, Kane CJ, Aronson WJ, et al. Do racial differences in prostate size explain higher serum PSA concentrations among black men? Urology. 2007;69(6):1138–42.CrossRefPubMedPubMedCentral
33.
go back to reference Moul J, Connelly R, Mooneyhan R, Zhang W, Sesterhenn IA, Mostofi FK, et al. Racial differences in tumor volume and prostate specific antigen among radical prostatectomy patients. J Urol. 1999;162(2):394–7.CrossRefPubMed Moul J, Connelly R, Mooneyhan R, Zhang W, Sesterhenn IA, Mostofi FK, et al. Racial differences in tumor volume and prostate specific antigen among radical prostatectomy patients. J Urol. 1999;162(2):394–7.CrossRefPubMed
34.
go back to reference Vollmer R. Race and the linkage between serum prostate-specific antigen and prostate cancer: a study of American veterans. Am J Clin Pathol. 2004;122(3):338–44.CrossRefPubMed Vollmer R. Race and the linkage between serum prostate-specific antigen and prostate cancer: a study of American veterans. Am J Clin Pathol. 2004;122(3):338–44.CrossRefPubMed
Metadata
Title
68Ga-PSMA-11 PET/CT in primary staging of prostate carcinoma: preliminary results on differences between black and white South-Africans
Authors
Mike Sathekge
Thabo Lengana
Alex Maes
Mariza Vorster
JanRijn Zeevaart
Ismaheel Lawal
Thomas Ebenhan
Christophe Van de Wiele
Publication date
01-02-2018
Publisher
Springer Berlin Heidelberg
Published in
European Journal of Nuclear Medicine and Molecular Imaging / Issue 2/2018
Print ISSN: 1619-7070
Electronic ISSN: 1619-7089
DOI
https://doi.org/10.1007/s00259-017-3852-8

Other articles of this Issue 2/2018

European Journal of Nuclear Medicine and Molecular Imaging 2/2018 Go to the issue